Search for: "Wells v. Wyeth Pharmaceutical, et al" Results 1 - 20 of 31
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 Jan 2023, 6:36 pm by admin
 Gislaved Gummi AB, 178 F. 3d 257, 263–264 (4th Cir. 1999) (citing cases); Wells v. [read post]
8 Apr 2019, 9:35 am by Schachtman
The relied-upon studies may well end up discredited, as well as the professional reputation of the expert witness. [read post]
25 Apr 2015, 11:03 am by Schachtman
See also Manual at 614 n. 198., citing Ofer Shpilberg, et al., The Next Stage: Molecular Epidemiology, 50 J. [read post]
3 Dec 2013, 7:54 am
Wyeth Pharmaceuticals, Nos. 12-6195, et al., slip op. (6th Cir. [read post]
14 Jun 2013, 12:13 pm by Schachtman
Home, et al., Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD), 373 Lancet  2125 (2009). [read post]
10 May 2012, 7:16 am
Mutual Pharmaceutical Co. et al, she alleged the drug was defectively designed because its risks outweighed its benefits, and the First U.S. [read post]
2 Mar 2012, 6:52 am by Bexis
  If you thought our prior Parisian post was boring – well this one’s just as boring, but even longer. [read post]
8 Feb 2011, 10:51 pm by Marie Louise
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New… [read post]